Ivănescu Ana-Maria 1, Oprea Mădălina 1, Coliță A. 1,2, Turbatu A. 1, Lupu Anca Roxana 1
1 Hematology Department – Coltea Clinical Hospital, Bucharest
2 Carol Davila University of Medicine and Pharmacy, Bucharest
Abstract
Chronic lymphocytic leukemia is a chronic lymphoproliferative disorder, indolent but heterogeneous in evolution and difficult to predict. Beside cases whith long lasting evolution even without specific treatment, the clinical practice often faces cases with advanced stages, poor prognostic factors and high risk of disease progression in which choosing the best treatment tailored to each patients is a difficult task. Classical chemotherapy schemes have been effective but combining them with or shifting to new therapeutic agents, along with improved investigation techniques, led to a significant increase in the complete remission rates as well as improvement of survival, without risks of disease progression. During and after therapy, patients need to be thoroughly monitored, the detection of minimal residual disease increasing the chance to discover, early in the process, unresponsive cases or relapses. Complete clinical investigations and paraclinical tests, performed at the onset of disease have an important contribution for the selection of the best therapeutic option and moment of treatment initiation.